{
  "abstract": "Introduction: The Evoque™ transcatheter tricuspid valve replacement (TTVR) system demonstrated superiority over optimal medical treatment (OMT) in the TRISCEND II trial. We aimed to evaluate the cost-effectiveness of TTVR in patients with severe Tricuspid Regurgitation (TR) from the French healthcare perspective.\n\nMethods: A state-transition Markov model was developed to assess the cost-effectiveness of Evoque™ TTVR versus OMT alone over a lifetime horizon. The modelled cohort reflected the TRISCEND II population. Health states were defined by TR severity (none/trace, mild, moderate, severe) and death. Transition probabilities, adverse events, and hospitalization rates were informed by TRISCEND II. Long-term survival outcomes were extrapolated by TR severity using published data. Utilities were estimated from the NYHA class distribution. Costs and health outcomes were discounted at 2.5% annually.\n\nResults: Evoque™ was associated with an incremental 1.76 life-years gained (LYG) and 1.63 quality-adjusted LYG (QALY). Incremental costs were €39 382 driven by device acquisition and procedure costs, resulting in an incremental cost-effectiveness ratio (ICERs) of €22 327/LYG and €24 109/QALY gained. Assuming no mortality difference in extrapolations, the ICER would increase to €86 428/QALY (+258%). The model was highly sensitive to assumptions on time horizon, utility, discount rate, and post-trial mortality extrapolation, leading to major uncertainty.\n\nConclusion: Evoque™ may represent a cost-effective strategy in severe TR patients; however, this should be interpreted with caution, as results rely heavily on extrapolated data and are subject to high structural and parameter uncertainty. The projected long-term benefits are largely model driven rather than empirically demonstrated, emphasizing the need for extended follow-up data.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "name": "Apolline Grangeon"
    },
    {
      "name": "Martin Connock"
    },
    {
      "name": "Peter Auguste",
      "orcid": "0000-0001-5143-3218"
    },
    {
      "name": "Jean François Obadia"
    },
    {
      "name": "Maurice Enriquez-Sarano"
    },
    {
      "name": "Benjamin Essayagh",
      "orcid": "0000-0002-7116-5529"
    },
    {
      "name": "Xavier Armoiry",
      "orcid": "0000-0002-2145-6723"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5myz8bdqyter8.bib",
  "cited_by": 0,
  "doi": "10.1093/eschf/xvag137",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13720647/",
  "id": "5myz8bdqyter8",
  "issns": [
    "2055-5822"
  ],
  "landing_url": "https://doi.org/10.1093/eschf/xvag137",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00200"
    ],
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2705|Cardiac Valve Diseases and Treatments"
    ]
  ],
  "openalex": "W7160910226",
  "pdf_url": "https://academic.oup.com/eschf/advance-article-pdf/doi/10.1093/eschf/xvag137/68275185/xvag137.pdf",
  "pmcid": "PMC13720647",
  "pmid": "42120016",
  "published": "2026-05-13",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/5myz8bdqyter8.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T12:21:29Z",
      "native_id": "PMC13720647",
      "source": "pmc",
      "url": "https://doi.org/10.1093/eschf/xvag137"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2705|Cardiac Valve Diseases and Treatments",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial",
  "title_text": "Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:21:29Z",
  "url": "https://research.draconitic.com/paper/5myz8bdqyter8",
  "venue": "ESC Heart Failure",
  "versions": []
}